ERBB2 and breast cancer: We found that PI-3 K/Akt-dependent upregulation of Survivin played a vital role in erbB3-mediated paclitaxel resistance in erbB2+ breast cancer cells, and specific knockdown of Survivin abrogated the resistance [76].